Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glatiramer Acetate 40 mg in ALS
NCT00326625Phase 2Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Jul 2006
- Primary completion
- Jun 2008
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 6
01
Overview
A Phase 2 trial of glatiramer acetate in amyotrophic lateral sclerosis (ALS), sponsored by Teva Pharmaceutical Industries Ltd.. Started Jul 2006; status: completed.
02
Drugs
glatiramer acetate
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT00326625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00326625.